Clarifying the mechanism of action of cladribine in relapsing multiple
Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Cladribine
DNA inhibitor
What it measured
Main measures
Changes in the T cell receptor repertoire (CD4 and CD8 T cells) and B cell receptor repertoire (CD19 B cells) 3 and 12 months after start of first treatment course (as compared to baseline) will be assessed using thawed PBMC by deep sequencing of the T cell receptor and the B cell receptor repertoire.
Immune response
Other measures (1)
• Changes in the T cell receptor repertoire (CD4 and CD8 T cells) and B cell receptor repertoire (CD19 B cells) 12 months after start of second treatment course (as compared to baseline) will be assessed using thawed PBMC by deep sequencing of the T cell receptor and the B cell receptor repertoire.
Immune response
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Signed informed consent form (ICF) Exclusion: 1. Hypersensitivity to the active substance or to any of the excipients of the study medication
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Analysis of the T cell receptor repertoire of CD4 and CD8 T cells, and the B cell receptor repertoire of CD19 B cells before and during the first year after onset of cladribine treatment initiation.
Papers
Loading reviews and guidelines…
Related trials
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Mult
Phase 4 · Not yet recruiting
Still running
- No Evidence Of Disease Activity After Autologous Haematopoietic Stem C
Phase 2 · Stopped early
Stopped
- Cladribine Tablets Level of Response Predictors in Clinical Practice (
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No results found
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
History
Started
Jun 2019